Company intelligence / Profile preview

Verisfield

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Verisfield specializes in developing and marketing generic pharmaceutical products and those with improved or differentiated physicochemical characteristics. The company has launched products across many therapeutic categories, including innovative compositions protected by patents. Clinical activity includes Phase 3 trials for bioequivalence of generics such as clindamycin vaginal ovules versus branded comparators, with approved drugs like metronidazole hydrochloride on the market.[1][2][3][4]

Therapeutic areas: OtherInfectious Diseases
Modalities: Small molecules (primarily generics and improved formulations)[1][2][3]
Industry: Biotech

Drug pipeline

1 asset

Mycomycen

Unknown

Beyond the preview

Go deeper on Verisfield.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verisfield.

Explore the full profile